Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant

France's Poxel has completed the out-licensing of its oral Phase III-ready diabetes therapy, the glimin, imeglimin, that could be transformative...

      

Related Stories

• Lupin Upbeat On Biosimilar Etanercept After Q3 Profit Plunge
• Small Study Offers Hope For PARP/PD-L1 Combos In Prostate Cancer
• Tech Transfer Roundup: Deerfield, Broad Institute Alliance Selects Two Cancer Programs

 

Original Article: Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant

More From BioPortfolio on "Poxel's Phase III Oral Diabetes Therapy Taken Up By Roivant"